|
Volume 19, Issue 3 (May 2017) 19, 346–349; 10.4103/1008-682X.172826
Mutation of MED12 is not a frequent occurrence in prostate cancer of Korean patients
Nara Yoon1, Sharon Lim1, So Young Kang1, Ghee Young Kwon1, Hwang Gyun Jeon2, Byong Chang Jeong2, Seong Il Seo2, Seong Soo Jeon2, Hyun Moo Lee2, Han Yong Choi2
1Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 135-710, Korea
2Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 135-710, Korea
Correspondence: Dr. GY Kwon (geeo@skku.edu)
Date of Submission 12-Jun-2015 Date of Decision 26-Aug-2015 Date of Acceptance 23-Nov-2015 Date of Web Publication 26-Feb-2016
| Abstract |
|
Prostate cancer is one of the major health care problems, but the molecular pathogenesis has been relatively insufficiently elucidated. Recently, whole exome sequencing of prostate cancer identified recurrent mutations involving MED12 in Caucasian patients, which finding was not reproduced in one subsequent study by Sanger sequencing. Thus, we investigated mutation status of MED12 in exons 2 and 26 by Sanger sequencing in 102 radical prostatectomy cases from Korean patients. The analysis found the mutation in none of the cases. Therefore, MED12 mutation does not appear to represent a significant molecular alteration in this cohort of patients according to the analysis by the traditional "gold standard."
Keywords: mediator complex subunit 12; mutation analysis; prostate cancer; prostate neoplasms
Full Text |
PDF |
|
| |
| Browse: 1231 |
|
